Trial Profile

A Phase I/II, Dose Escalation Study To Assess The Safety and Tolerability of VAL201 In Patients With Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 12 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VAL 201 (Primary)
Indications Carcinoma; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man
Acronyms VAL201-001
Sponsors ValiRx

Most Recent Events

20 May 2020 Status changed from completed to discontinued.
14 Feb 2020 Status changed from recruiting to completed.
06 Jan 2020 According to an ValiRx media release, the company has raised 200,000 pounds of gross proceeds through the issue of 200,000,000 new ordinary shares. These net proceeds of the Placing will be used to analyse this Phase I/II clinical trial of VAL201.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com